The impact of Indigenous American-like ancestry on risk of acute lymphoblastic

leukemia in Hispanic/Latino children

Jalen Langie[1,2], Tsz Fung Chan[1,2], Wenjian Yang[3], Alice Y. Kang[4], Libby Morimoto[4], Daniel O.

Stram[5], Nicholas Mancuso[1,2], Xiaomei Ma[6], Catherine Metayer[4], Philip J. Lupo[7,8], Karen R.

Rabin[7,8], Michael E. Scheurer[7,8], Joseph L. Wiemels[1,2], Jun J. Yang[3], Adam J. de Smith[1,2,10],

Charleston W.K. Chiang[1,2,9,10]

[1] Center for Genetic Epidemiology, Department of Population and Public Health Sciences, University of

Southern California Keck School of Medicine, Los Angeles, CA, USA.

[2] USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

[3] Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital,

Memphis, Tennessee, USA.

[4] School of Public Health, University of California Berkeley, Berkeley, CA, USA.

[5] Department of Population and Public Health Sciences, University of Southern California Keck School of

Medicine, Los Angeles, CA, USA.

[6] Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.

[7] Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX,

USA.

[8] Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX, USA.

[9] Department of Quantitative and Computational Biology, University of Southern California, Los Angeles,

CA, USA.

[10] Co-senior authors

Abstract:

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, with Hispanic/Latino

children having a higher incidence of ALL than other racial/ethnic groups. Among genetic variants

previously implicated in ALL risk, a number of them were found to be enriched in Indigenous

American (IA)-like ancestries and inherited by many Hispanic/Latino individuals. However, due to

potential confounding from environmental factors, the association between IA-like ancestry and

risk for ALL has remained unclear. In this study, we characterized the impact of IA-like ancestry

on overall ALL risk and on the frequency and effect size of known risk alleles, while accounting

for non-genetic correlates of ancestry. Contrary to previous findings, we found that global IA-like

ancestry was not significantly associated with ALL risk after adjusting for socio-economic

indicators. On the other hand, locally at known ALL risk regions, we uncovered that increasing

copies of the IA-like haplotype were positively and significantly associated with ALL risk (*e.g.* the

IA-like haplotype had ~1.33 times the odds of harboring the risk allele compared to non-IA-like

haplotypes), but we found no evidence of interaction between genotype and ancestry in relation

to ALL. Admixture mapping identified replicable association signals at chr7p12.2 and chr10q21.2,

consistent with the benefit of leveraging genetic ancestry in identifying genetic risk loci. Taken

together, our results suggest that increased risk of ALL in Hispanic/Latino children may be

conferred by higher frequency of risk alleles within IA-like ancestry, and that local ancestry-based

analyses are robust stratagems to elucidate genetic etiology of disease.

Introduction:

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for

25% of malignancies before the age of 20 (ref. [1]). The long-term survival rate of the disease in

children is upwards of 85-90% [2], but survival rate decreases to approximately 40% after

relapse[3–6] and 30-40% in individuals over the age of 35. Despite decades of investigation into

ALL risk, the etiology of the disease is not well understood and disparities in risk persist.

Children of Hispanic/Latino ethnicity have 1.4 and 2 times the risk of developing ALL compared

to their Non-Latino White and Black counterparts, respectively[7] . This disparity in risk widens in

margin for Hispanic/Latino adults[7] and is specific to the B-cell immunophenotype – which

comprises approximately 85% of cases[8] . While environmental factors are involved in this

increased risk, genetic factors, which have been historically understudied in this population[9,10],

likely contribute in part to this disparity[11,12]

69
Genomic, migrational, and ecological data strongly suggest a complex genetic etiology of ALL,

both broadly across humans and within diverse Latin American populations. Most directly,

previous genome-wide association studies (GWAS) have estimated the heritability of ALL to be

approximately 18-21% in both Hispanic/Latino and Non-Latino White populations, and

approximately 24% of familial relative risk has been attributed to known ALL risk variants[13–15] .

Consistent with these estimates, GWAS have identified a number of loci associated with ALL

susceptibility, including risk alleles located near genes such as *IKZF1*, *ARID5B*, *GATA3*, and *ERG*

that appear to have higher frequency or stronger effects in Hispanic/Latino populations[12,16–18].

Previous migration studies have indicated that non-native- and US-born Hispanic/Latino

individuals have comparable rates of B-cell ALL to each other, and both have higher (~2.13 times)

incidence rates compared to their Non-Latino White counterparts[19,20]. Furthermore, ecological

data has indicated that countries with the highest age standardized incidence rates of ALL were

in Latin America (*i.e.* Honduras and Mexico), while countries with the lowest incidence rates were

in Africa, with European countries exhibiting intermediate incidence[21,22] .

Notable amongst populations with differing incidence rates of ALL is the presence or dominance

of a particular ancestry component. Due to the unique demographic history of Latin America,

Hispanics/Latino populations are admixed - drawing ancestral components from the American,

European, and African continents[23,24] . Previous literature has alluded to associations between

Indigenous American (IA)-like ancestry and ALL, suggesting that every 20% increase in IA-like

ancestry was associated with a 20% increase in odds of developing B-cell ALL[25]. Because

Hispanics/Latinos inherited a significant proportion of their genetic ancestries from Indigenous

Americans (though there is geographical heterogeneity across the Americas), this association

was presumed to explain the migration and ecological findings above. However, global ancestry

can be confounded by non-genetic factors such as socio-economic status[26], which was not

considered in previous analyses[25] . Further exploration of the association between IA-like

ancestry and ALL risk would need to account for this potential confounding.

Given the important role of genetic factors and genetic ancestry in ALL risk, we undertook a

systematic admixture analysis in the largest ALL cohort of self-reported Hispanic/Latino children

to date. Here, we sought to clarify the association between IA-like ancestry and ALL risk through

a study design that would better account for non-genetic confounders and leveraged local

ancestry analyses, which are less susceptible to confounding by environmental factors and have

previously yielded promising results in examining ancestry-ALL relationships[30]. We investigated

both inferred global ancestry across the genome and local ancestry at known ALL loci for

associations with risk. Further, we employed admixture mapping[27], which is best powered to

detect loci that exhibit frequency differences between ancestries and may underlie the risk

differences between populations[28,29].

We note that, given our goal to further understand the disparity in ALL risk epidemiologically

observed among Hispanic/Latino children, we inferred the genetic ancestries and characterized

their associations with ALL risk in self-reported Hispanic/Latino individuals. We defined genetic

ancestries at the continental (e.g. Africa, Europe, and Americas) level, which represents patterns

of genetic similarities across geographical space over the last ~10-50k years due to human

migrations and isolation-by-distance. These relatively distinct components of ancestries, though

arbitrarily defined, are only recently reunited in admixed populations, such as in individuals of

Hispanic/Latino origin. These components are inferred and defined relative to reference

populations available to us and are leveraged to uncover associations with traits in this research

setting but are invariably a simplified representation of the complex nature of genetic ancestries.

We thus append the suffix "-like" to refer to these ancestries to remind the reader of this

simplification and uncertainty[30].

Methods:

Study Subjects and Quality Control

We use the term "Hispanics/Latinos" as a population descriptor of our study subjects to align with

both the self-reported race/ethnicity categories and the definitions of the USA Office and

Management Budget[31], while acknowledging that we focus on individuals of Latin American origin.

Our analysis utilized the following cohorts of self-reported Hispanic/Latino study participants: the

California Cancer Linkage Project (CCRLP), the Kaiser Resource for Genetic Epidemiology

Research on Aging Cohort (Kaiser-GERA), the California Childhood Leukemia Study (CCLS),

Children's Oncology Group (COG), Multi-Ethnic Study of Atherosclerosis (MESA), the Adolescent

and Childhood Cancer Epidemiology and Susceptibility Service for Texas and Reducing Ethnic

Disparities in Acute Leukemia (ACCESS/REDIAL), and the Hispanic Community Health

Study/Study of Latinos (HCHS/SOL). All relevant information on sample size, arrays, study

design, and references/dbGaP accession numbers can be found in **Table 1**. Following the

practice in previous studies[12,13,32], cases from CCRLP were augmented with external controls

from Kaiser-GERA genotyped on a similar array. Cases from COG were paired with external

controls from MESA and ACCESS/REDIAL cases were paired with external controls from

HCHS/SOL. HCHS/SOL was a multi-center study, with study participants being ascertained from

Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California. The SOL San Diego

center was chosen as controls for ACCESS/REDIAL due to similarity in the first 2 principal

components and estimated ancestry distributions (**Supplementary Figures 1-2**).

Study	In-Text Name/ Acronym	Study Design	N	Genotype Array	Reference or Accession Number	Usage
California Cancer Linkage Project	CCRLP	Population Based case-control study	4033	Affymetrix Axiom World Array	Wiemels et al., 2018 (ref [32])	Global and local ancestry analyses; Discovery Admixture Mapping Cohort (combined with Kaiser-GERA)
Kaiser Resource for Genetic Epidemiology Research on Aging Cohort	Kaiser-GERA	Cohort study (controls only)	6417	Affymetrix Axiom World Array	phs000788.v1.p2	Discovery Admixture Mapping Cohort (combined with CCRLP)
California Childhood Leukemia Study	CCLS	Population Based case-control study (cases and controls)	1120	Illumina OmniExpress v.1	Ma et al., 2004 (ref [33])	Global and local ancestry analysis; Replication cohort
Children's Oncology Group (AALL0232, COG9904/9905)	COG	Clinical Trial (cases only)	836	Genome-Wide Human SNP Array 6.0	phs001350.v1.p1	Replication Cohort (combined with MESA)
Multi-Ethnic Study of Atherosclerosis	MESA	Cohort Study (controls only)	1118	Genome-Wide Human SNP Array 6.0	phs000209.v13.p3	Replication Cohort (combined with COG)
Adolescent and Childhood Cancer Epidemiology and Susceptibility Service for Texas and Reducing Ethnic Disparities in Acute Leukemia	ACCESS/ REDIAL	Hospital Cases (cases only)	510	Illumina Global Screening Array	Harris et al., 2023 (ref [34])	Replication Cohort (combined with HCHS/SOL)
Hispanic Community Health Study/Study of Latinos	HCHS/SOL	Cohort Study (controls only)	2285	Illumina Omni2.5M array	phs000810.v2.p2.c2; phs000810.v2.p2.c1	Replication cohort (combined with cases from Texas)

Table 1: All cohorts included in the analysis. *Information includes title, design, sample size, genotype array, dbGaP accession*

number or reference, and how each study was used in our analysis.

All analyses were limited to autosomes. Within each study, SNPs and individuals were removed

based on the following pre-defined quality control thresholds: SNP call rate < 0.98, MAF < 0.01,

$p_{HWE} < 1 \times 10^{-5}$, high relatedness ($\hat{\pi} > 0.2$), Genome Heterozygosity Rate > 6 standard

deviations from the mean, or sample call rate < 0.95. Palindromic SNPs were also excluded as

they could impact imputation accuracy due to unidentified strand flip or inversion between genome

build[35] . The number of individuals and SNPs remaining can be found in **Supplementary Table**

1. Local ancestry was inferred using RFMIX[36]. Reference haplotypes were obtained from the

genome aggregation database (gnomAD)[37] version 3, including 708 African, 671 Non-Finnish

European, and 94 Indigenous American individuals previously chosen for ancestry inference in

Hispanics/Latinos[38] . After restricting to the intersection of SNPs across each paired dataset, each

dataset was imputed separately using the TopMed Imputation Server[39]. We observed systemic

differences in imputation quality as measured by the imputation R^2 between cases and external

controls, presumably due to batch effects in data generation or subtle differences in ancestry

compositions between cohorts and differential imputation accuracies across populations[40].

Consequently, for all comparisons of cases to controls, we imposed filters such that only SNPs

with an imputation $R^2 > 0.30$ in both cases and controls and a R^2 difference < 0.15 between cases

and controls were included in the analysis.

<u>Global Ancestry Analyses</u>

Global ancestry for each study participant was calculated by averaging local ancestry estimates

across the genome. We performed logistic regression of ALL case-control status on global IA-like

ancestry in CCRLP and CCLS, studies in which indicators of socio-economic status (SES)

variables were available. Covariates included African-like ancestry, sex, and SES indicators

(highest education obtained by a parent and annual household income). Income was categorized

in 6 strata, in accordance with its treatment in CCLS[41] : <\$15,000, \$15,000-\$29,999, \$30,000-

\$44,999, \$45,000-\$59,999, \$60,000-\$74,999, and >\$75,000. In CCLS, highest educational

attainment of either parent was divided into 4 categories: Less than elementary school, high

school, some college, and a bachelor's degree or higher. In CCRLP, the strata were less than 9th

grade, 9th-12th grade, and some college or more. Both SES indicators were treated as ordinal

categorical variables, in which the lowest category was used as a reference. Linearity

assumptions were assessed using residual and QQ plots. Analysis was carried out using R v.4.3.1

(ref. [42]).

<u>Enrichment of risk allele on IA-like ancestry haplotypes</u>

We performed local ancestry analyses at known ALL loci, based on the list provided in ref. [11]. We

excluded the T-cell ALL-specific association locus at *USP7*[43] given that the increased risk of ALL

in Hispanics/Latinos is limited to B-cell ALL. We restricted analyses to remaining SNPs that were

independent at the local ancestry level (*i.e.* choosing SNPs that were not in admixture linkage

disequilibrium; N=20) using PLINK's clumping algorithm[44]. SNPs were clumped if the diploid local

IA-like ancestry assignments covering the SNPs were 90% correlated and within 10 Mb of each

other.

A total of three analyses were performed using local ancestry estimates. First, across known ALL

loci[11], we cross-tabulated local genetic ancestry (number of copies of the IA-like, African-like, or

European-like haplotypes) and risk allele dosage to identify association of risk alleles with

ancestry. To establish a null distribution to which we would compare our observed ancestry-risk

allele association, we randomly selected 1000 sets of 20 frequency-matched alleles from across

the genome, without replacement. Differences between the null and known loci distributions were

evaluated via a Chi-Squared Goodness of Fit test. We restricted this analysis to CCRLP and

CCLS controls, to approximate the frequency of the risk allele in the general population. Second,

we performed a logistic regression of ALL case-control status on IA-like ancestry dosage at each

locus, including as covariates global African-like and European-like ancestry, and sex, to evaluate

how likely is the IA-like ancestry associated with increasing ALL risk. Third, to test for presence

of heterogeneous effect sizes across ancestries, we performed logistic regression of ALL case-

control status on risk allele genotype, IA-like ancestry dosage, sex, the first 20 principal

components, and an interaction term of local ancestry and risk allele dosage. Analyses were

carried out either using PLINK v2.0 (ref. [45]) or R v.4.3.1 (ref. [42]).

<u>Admixture mapping, regional association testing, and replication</u>

We performed a genome-wide scan for loci in which IA-like ancestry was associated with ALL

risk. We regressed ALL case-control status on the local IA ancestry dosage, global African-like

and European-like ancestry, sex, and the first 20 principal components. We performed this

analysis in CCRLP/Kaiser as our discovery dataset. The significance threshold for genome-wide

admixture mapping was 5.7×10^{-5}, as suggested in literature previously for Hispanic/Latino

populations[46,47].

We fine-mapped putative admixture association region through single-variant association testing

in the same dataset. The admixture peak region[48] was defined as a range of positions that

contains all SNPs with a -log10(P) between -log10(P_{am}) and -log10(P_{am}) − 1, with P_{am} representing

the p-value associated with the lead SNP from admixture mapping. Genotypes of all imputed

SNPs within this region passing QC filtering were tested via logistic regression, with sex and the

first 20 principal components as covariates. Significance threshold for each region were computed

using 1000 rounds of permutation of case-control labels, choosing the threshold that controls for

the 5% false discovery rate. We attempted to replicate the association at the lead variants from

regional association testing and conditional analysis in additional Hispanic/Latino cohorts: CCLS,

COG/MESA, and SOL-SD/REDIAL. The replication cohorts were meta-analyzed together by

inverse variance weighting in the software *METAL*[49].

<u>Evaluating the impact of using self-reported race/ethnicity labels versus genetic inferred ancestry</u>

We opted to perform admixture mapping using all self-reported Hispanic/Latino individuals to be

inclusive and avoid forming study exclusion criteria based on estimated genetic ancestry.

However, alternative approaches could choose to include participants based on inferred genetic

ancestries. To examine, in our context, the impact of informing study inclusion based on

genetically inferred ancestry, we implemented a software, Harmonizing Ancestry and Race

Ethnicity[50] (HARE; Fang et. al, 2019) on genetic data from CCRLP/Kaiser-GERA

(**Supplementary Figure 3** . HARE is a two-step machine learning-based algorithm that identifies

individuals who may have discordant self-identified race/ethnicity (SIRE) and genetically inferred

ancestry (GIA) information, given the mapping of the two learned from the rest of the dataset. The

first step is a training phase in which genetically inferred ancestry based on principal components

are used to predict available self-reported race/ethnicity in a support vector machine (SVM). The

second step is HARE strata assignment, in which the highest probability of being assigned to a

stratum is contrasted with the probability that the individual belongs to their self-reported stratum

using preset thresholds. If the ratio of the probabilities exceeds a pre-defined threshold, an

individual with existing SIRE could be assigned as missing (*i.e.* removed from analysis), while an

individual without SIRE would be assigned into the top predicted strata.

We applied HARE with the default parameters and thresholds[50], training a multi-class SVM with

a radial kernel on the first 30 principal components (calculated using PLINK[45] v2.0) of genotype

data from individuals across all self-reported race/ethnicity groups from CCRLP/Kaiser-GERA

(10,450 Hispanic/Latino, 2,191 Non- Latino African, 5,335 Non-Latino East Asian, 58,503 Non-

Latino European individuals). We first evaluated if the HARE algorithm would exclude any study

participants due to discordance between SIRE and GIA. We also assessed the rate of

discordance between SIRE and GIA by performing 10-fold cross validation in which we randomly

masked the SIRE information of 10% of study participants for each race/ethnicity group in each

trial. This assessment simulates a scenario where one may define study exclusion criteria based

on comparing the GIA to a known reference panel. Percent discordance was defined as the

number of individuals classified as missing or as a stratum not corresponding to the masked SIRE

label. We then investigated the impact of this study exclusion criteria on our admixture mapping

result.

IRB Statement:

This study was approved by the institutional review boards of the California Health and Human

Services Agency, the University of Southern California, Children's Oncology Group, Baylor

College of Medicine, Yale University, and University of California, Berkeley. All study participants

were de-identified and newborn bloodspots from the CCRLP were obtained via a consent waiver

from Committee for the Protection of Human Subjects of the State of California.

Results:

The association between global Indigenous American-like ancestries, ALL risk, and SES

indicators

Previous studies have identified a significant and positive association between global IA-like

ancestries and ALL risk[25] (Walsh et al., 2013) but did not adjust for socioeconomic status (SES)

variables that often confound ancestry-disease associations. To quantify the effects of IA-like

ancestry on ALL risk, we tested the association between ALL case-control status and global IA-

like ancestry, while adjusting for African-like ancestry, sex, as well as covariates that are proxies

for SES, such as highest parental education and annual household income. We performed these

assessments for all self-reported LAT individuals in both CCRLP (excluding Kaiser-GERA

controls; N = 4033) and CCLS (N = 605), as both of these cohorts have available SES variables,

contained internal controls and are less likely to be confounded due to their study design. In

CCLS, IA-like ancestry was significantly associated with ALL risk, prior to including SES indicators

in the model, as previously reported (Walsh et al., 2013). In the base model adjusting for sex and

African-like ancestry, a 20% increase in IA-like ancestry was associated with a 23% (OR: 1.23,

95% CI: 1.07-1.42; P = 0.003) increase in odds of developing ALL. However, this association

appears confounded, as inclusion of SES covariates strongly attenuated the strength of

association (OR: 1.12; 95% CI: 0.96-1.31) and case/control status is no longer significantly

associated with IA-like ancestry ($P = 0.$159$;$ **Supplementary Table 2**). In CCRLP, IA-like ancestry

was not significantly associated with ALL risk in the base model adjusting for only African-like

ancestry and sex, and did not qualitatively change when SES covariates were included

(**Supplementary Table 2**). Regression analysis between the SES variables and ALL case-

control status and ancestry, respectively, further supported the suggestion that socio-cultural

factors can act as confounders in ancestry-trait relations. For instance, we observed higher

income to be associated with lower risk of disease (*e.g.* 0.27 – 0.76 times the odds of developing

ALL; **Supplementary Tables 3-4**), and higher European-like ancestry is associated with higher

socio-economic status (**Supplementary Tables 5-6**). Together, because SES measures can

correlate with both ancestry and disease risk, the previously observed association between IA-

like ancestry and ALL risk (Walsh et al., 2013) may have been confounded.

Known ALL risk loci are enriched among Indigenous American-like ancestral haplotypes

While global ancestry association analyses can be confounded by socioeconomic indicators, use

of local ancestry to identify associations at risk loci may be more robust. Further, the absence of

an association between IA-like ancestry and ALL risk globally would not necessarily preclude an

association locally at known risk loci. Thus, we performed three analyses leveraging the pattern

of local ancestry at known B-cell ALL risk loci[11] (**Supplementary Table 7**) to examine if the risk

alleles are found more frequently or show larger effects on IA-like ancestry haplotypes. First, we

tabulated the proportion of times the risk allele at known ALL loci is associated with the African-

like, IA-like, or European-like ancestry haplotypes, and compared these to the proportions found

across 1000 sets of SNPs randomly selected across the genome and matched by the risk allele

frequencies. Across a total of 20 quasi-independent ALL SNPs (**Methods**)**,** the risk alleles were

found on the African-like, IA-like, and European-like ancestry haplotypes 5.76%, 45.35%, and

48.88% of the time, respectively, in CCRLP. This significantly deviates from the genome-wide

expectation (4.83%, 43.33%, and 51.85% for African-like, IA-like, and European-like ancestry

haplotypes; p-value = 1.04×10^{-36} by a chi-square goodness-of-fit test), with IA-like haplotypes

showing a significant enrichment in association with the risk alleles. We also replicated this

observation in CCLS, with IA-like haplotypes enriched with ALL risk alleles (p-value = 1.629×10^{-9}

). Consistent with this finding, the IA-like haplotypes have 1.32-1.33 (95% CI: 1.29 - 1.36 in

CCRLP, 1.26-1.41 in CCLS) times the odds of carrying the risk allele compared to Non-IA-like

haplotypes (p = 5.61×10^{-88} and 2.61×10^{-23} in CCRLP and CCLS, respectively; **Supplementary**

Table 8).

In the second local ancestry analysis, we regressed ALL case-control status on the number of

copies of IA-like ancestry segments locally at each known ALL locus, while adjusting for sex and

global African and European ancestry proportions. Because we anticipate that risk alleles for ALL

are found disproportionately on IA-like haplotypes across these loci, we would expect that IA-like

ancestries show an enrichment of association increasing the risk of ALL in the setting of admixture

mapping studies. Indeed, we found a positive association of IA-like ancestry with ALL at 14 out of

20 known B-cell ALL loci. At all loci in which IA-like ancestry was nominally significantly (p < 0.05)

associated with ALL, IA ancestry was positively associated with risk (Binomial test, p = 0.008

Table 2). To confirm that the known risk alleles were in fact driving the ancestry association, we

included risk genotype as an additional covariate in each model. At each locus, upon adjustment

for risk genotype, the association between IA-ancestry and ALL risk reduced in significance

(**Supplementary Table 9**). Taken together, our results suggest that IA-like haplotypes are

enriched for association with increased ALL risk at known loci, driven by increased frequency of

risk allele.

340
341

Gene	Chr	Location	OR	L95	U95	P-value[a]
BCL11A	2	2p16.1	0.94	0.86	1.02	0.138
RPL6P5	2	2q22.3	1.01	0.93	1.10	0.751
C5orf56	5	5q31.1	1.07	0.98	1.17	0.113
BAK1	6	6p21.31	0.946	0.87	1.03	0.208
MYB/HBS1L	6	6q23	0.99	0.91	1.07	0.749
IKZF1	**7**	**7p12.2**	**1.32**	**1.21**	**1.43**	**2.990 x 10⁻¹⁰**
CCDC26	8	8q24.21	0.93	0.85	1.01	0.084
CDKN2A/2b	9	9p21.3	0.93	0.86	1.02	0.115
TLE1	9	9q21.31	1.04	0.96	1.13	0.358
GATA3	**10**	**10p14**	**1.14**	**1.04**	**1.24**	**0.003**
BMI1/PIP4K2A	**10**	**10p12.2/10p12.31**	**1.16**	**1.07**	**1.27**	**5.422 x 10⁻⁴**
ARID5B	**10**	**10q21.2**	**1.29**	**1.19**	**1.41**	**4.924 x 10⁻⁹**
JMJD1C	**10**	**10q21.3**	**1.27**	**1.16**	**1.38**	**5.383 x 10⁻⁸**
TET1	**10**	**10q21.3**	**1.15**	**1.06**	**1.25**	**0.001**
LHPP	10	10q26.13	0.97	0.89	1.06	0.508
ELK3	**12**	**12q23.1**	**1.10**	**1.01**	**1.19**	**0.038**
CEBPE	**14**	**14q11.2**	**1.10**	**1.01**	**1.20**	**0.022**
IKZF3	17	17q21.1	1.03	0.95	1.11	0.515
IGF2BP1	17	17q21.32	1.02	0.93	1.11	0.728

ERG	21	21q22.2	1.02	0.93	1.11	0.711

Table 2: Indigenous American-like ancestry is positively associated with risk at known ALL

loci. *ALL case-control status was regressed on local Indigenous ancestry dosage, African-like*

and European-like global ancestries, and sex[a]. Loci that reach nominal significance (P < 0.05) are

*in **bold**)*

In addition to ALL risk alleles being found more prevalently on IA-like haplotypes, risk alleles may

also exert larger (or smaller) effects on ALL when they are found on the IA-like background.

Therefore, for the third local ancestry analysis, we tested for effect size heterogeneity by including

a SNPxAncestry interaction term in the standard association testing model. After Bonferroni

correction, no significant interactions between genotype and local IA-like ancestry were observed

in either CCRLP or CCLS, or when the two cohorts were combined (**Supplementary Table 10**).

We additionally found no evidence of interaction between global IA ancestry and genotype

(**Supplementary Table 11**). Therefore, we found no evidence that ALL risk alleles may exert

larger effects on an IA haplotype than on other haplotypic backgrounds.

Admixture mapping proposes putative novel ALL loci associated with Indigenous American-like

ancestry.

Although results from our global ancestry analysis showed minimal association between IA-like

ancestry and ALL risk after adjusting for SES indicators, it does not preclude the possibility that

some risk alleles show drastic differences in frequency between ancestries, and thus are

amenable to being discovered through admixture mapping, particularly since we observed that

IA-like ancestries are enriched for association with risk alleles for ALL (**Table 2** above). We thus

performed admixture mapping using the CCRLP and Kaiser/GERA Hispanic/Latino cohort as

our discovery panel (1930 cases and 6417 controls). Our discovery admixture mapping

analyses identified genome-wide significant (threshold = 5.7 x 10^{-5} ; see **Methods**) signals at

2q21.2, 7p12.2, 10q21.2, and 15q22.31. The loci on chromosomes 7 (*IKZF1*) and 10 (*ARID5B*)

are known, while those on chromosomes 2 and 15 are potentially novel (**Figure 2**).

371
Figure 2: Manhattan plot of the admixture mapping analysis. *The analysis identified signals*

at 2q21.2, 7p12.2, 10q21.2, and 15q22.31. The significance threshold is 5.7e-5.

We then fine-mapped each of the four admixture loci via single-variant regional association

testing (**Methods**), which uncovered the putative lead SNPs in each region to be 2:133605881

(p = 4.209 x 10^{-5}), 7:50395237 (p = 2.262 x 10^{-12}), 10:61959980 (p = 2.245 x 10^{-44}), and

15:66111790 (p = 3.011 x 10^{-4} ; **Table 3**). SNPs on chr2, 7, and 10 surpassed the regional

significance threshold after accounting the number of tests performed in each region via

permutation (**Methods**), and chr15 SNP was slightly below the threshold. These SNPs exhibit

allele frequency differences by ancestry group (**Table 3**), and conditioning on these SNPs also

generally attenuated the admixture mapping association (**Table 3)**. We sought replication of

these associations in additional Hispanic/Latino cohorts, including cases from CCLS, COG, and

REDIAL (see **Methods**), totaling 1,951 cases and 3,918 controls. In the meta-analyzed

replication cohorts, only the lead SNPs or other SNPs in LD with the lead SNPs on

chromosomes 7 and 10 were statistically significant (**Supplementary Table 12-13**).   Through

power calculations[51] , we found that, given observed odds ratios in the discovery cohort and

combined allele frequencies in the replication datasets, our replication analysis had only 1.2%

and 0.5% power to detect the associations on chromosomes 2 and 15, respectively; in contrast,

we had 17.8% power to identify the signal on chromosome 7 and 100% power to detect the

locus on chromosome 10.

While local ancestry is not likely to be associated with socio-cultural variables, such analyses

can still be confounded by population stratification (Mersha 2015). In our study, we opted to

include all self-reported Hispanic/Latino individuals in our admixture mapping analysis and

adjusted for potential confounding by including global ancestries as covariates in our admixture

mapping model. Nevertheless, use of genetically inferred ancestry is pervasive and often

heralded as a convenient, albeit arbitrary way of identifying racial/ethnic strata to better control

for confounding by population structure (Fang et al., 2019) To evaluate whether our use of self-

reported data may lead to starkly different results from using genetically inferred ancestry, we

employed the Harmonizing Ancestry Race Ethnicity algorithm (HARE; Fang et al., 2019) to

identify individuals whose self-reported race ethnicity labelled may not be consistent with

genetically inferred ancestry compared to a reference. Consistent with the goals of our study

and best practices in using population labels in human genetic studies[30], HARE does not

attempt to re-assign individuals to strata; rather, individuals with discordant self-report and

genetically inferred data are indicated and thus can be excluded from analysis.

Using all available self-reported race/ethnicity labels in the multi-ethnic CCRLP + Kaiser cohort,

we observed very low rates of discordance between HARE-predicted labels and the self-

reported labels (percent discordance = 0.47% overall, and 0.68%, 3.37%, 0.18%, and 0.54% for

AFR, EAS, EUR, and LAT study participants, respectively. **Supplementary Table 14**),

suggesting that in general there is not enough genetic evidence to exclude participants from

analysis (nor do we advocate for removing individuals from analysis on the basis of genetic

make-up alone). In a scenario where individuals might be missing self-reported race/ethnicity

labels, HARE can be used to predict the label based on a reference. We simulated such a

scenario using 10-fold cross validations, randomly masking in turn 10% of the cohort while using

the remaining 90% as the reference for the HARE algorithm to learn the relationship between

self-reported labels and genetically inferred ancestry (**Methods**). In this case, we observed the

algorithm to be less confident, recalling 61.5% of LAT individuals, compared to 77.5%, 82.6%,

and 86.9% of NLW, AFR, and EAS individuals, respectively. Of those not recalled back as

Latino, 63.5% were assigned as missing, 35.3% were assigned as Non-Latino White, 0.4%

were assigned as Non-Latino East Asian, and 0.8% were assigned as Non-Latino Black

(**Supplementary Table 15**). As a sensitivity analysis, we restricted our admixture mapping

analysis to the set of Hispanic/Latino individuals inferred by HARE across 10 cross-validation

trials**,** which produced a panel of 1,729 cases and 4,696 controls (**Supplementary Table 16**).

Overall, we observed high correlation in odds ratios (Pearson's correlation coefficient, r = 0.

913) and log *P*-values (r = 0.853), with a modest decrease in significance among variants with

P-values < 1 x 10^{-3}, including the four putative loci (**Supplementary Table 12; Supplementary**

Figures 5-6), likely reflecting the smaller sample size.

431
432
433

Chr	Pos (Hg38)	rsID	Locus	Ref	Risk	$OR_{Top\,SNP}$ (95% CI)	$P_{Top\,SNP}$	RAF^*_{EUR}	RAF_{AFR}	RAF_{IA}	Gene	P_{crude}	P_{adj}	Peak Region
2	134116620	rs117345013	2q21.2	T	C	1.22 (1.11, 1.72)	4.209×10^{-5}	0.010	0.000	0.390	Unknown	4.156×10^{-6}	0.005	133605881, 134236147
7	50390453	rs6969942	7p12.2	C	T	1.35 (1.25, 1.47)	2.262×10^{-12}	0.507	0.773	0.870	IKZFI	7.315×10^{-8}	0.002	50352094, 50457722
10	61959980	rs4948492	10q21.2	T	C	1.85 (1.59, 2.13)	2.245×10^{-44}	0.295	0.162	0.441	ARID5B	3.210×10^{-5}	0.202	61928110, 62306779
15	65877726	rs12438510	15q22.31	G	A	1.23 (1.10,1.39)	3.011×10^{-4}	0.000	0.000	0.340	RAB11A	3.916×10^{-5}	6.718×10^{-5}	65540837, 66146213

442
443
Table 3: ***Odds Ratios, 95% CI's, and p-values of top SNPs from regional association testing, under the admixture peak, as***

well as the crude and adjusted p-values of the admixture mapping tag SNP. *The regional significance thresholds, determined via*

permutation to account for the regional multiple testing burden, are 7.906x10^{-5}, 6.256x10^{-4}, 1.905x10^{-3}, and 1.270x10^{-4} for 2q21.2,

7p12.2, 10q21.2, and 15q22.31, respectively.*Risk allele frequencies (RAF) per ancestry group were obtained from European

(Orcadian, Russian, Tuscan, French, Basque, Bergamo, Sardinian, Adygei), African (Bantu, Mbuti, Biaka, San, Yoruba, Mandenka),

and Indigenous American (Surui, Karitiana, Maya, Pima, Colombian) superpopulation data from the Human Genome Diversity Project

(accessed from the Genome Aggregation Database[38] v4).

Discussion:

Motivated by the increased risk of ALL in Hispanic/Latino children, we carried out a systematic investigation into the impact of IA-like ancestry on childhood ALL risk, both at the local and global level. We found that, socio-economic status indicators confound the relationship between global IA-like ancestry and ALL risk, and adjustment for these variables attenuates the association. The lack of global ancestry association, however, did not preclude an association at the local level, as IA-like ancestry was significantly associated with ALL risk across known loci and risk alleles segregated with the IA haplotype more often than expected. On the other hand, we found no interaction between IA-like ancestry and the risk genotype at either the local or global levels, suggesting that there is little evidence the risk alleles exert different effects in different ancestry contexts. Together, these results suggest that, in addition to environmental factors, risk alleles present in higher frequencies in IA populations may contribute to Hispanic/Latino individuals' excess risk of B-cell ALL.

Further, our in-depth investigation into inferred genetic ancestry also adds to and clarifies previous findings. A previous study found a positive, statistically significant association between global IA-like ancestry and ALL risk[25] . This result may have been affected by selection bias, due to the lower participation of controls than cases in lower SES areas[52]. Associations between global ancestries and disease risks are often reported, but these associations are often attenuated once non-genetic factors are included in the model or when a family-based design is used[53,54]. Indeed, observed associations between ancestry and type-2 diabetes risk in Hispanic/Latinos[26] and between ancestry and hypertension and lung cancer in African Americans[55,56] were attenuated once socio-economic covariates were accounted for. In our analysis of the CCLS dataset, we found that the association of ALL risk with global IA-like ancestry was attenuated and no longer statistically significant (though trending in the positive direction) after adjusting for income and education level. We acknowledge that disentangling the association between global genetic

ancestry and ALL risk is complex, especially given the observed correlations between SES

indicators, ALL risk, and genetic ancestry reported in this study and elsewhere[57,58]. In the CCRLP,

however, in which controls were ascertained through statewide birth records[32] and thus should

not be impacted by selection bias, we found no significant association between genetic ancestry

and ALL risk.

Our admixture mapping identified associations on chromosomes 2, 7, 10, and 15, but SNPs at

the putatively novel loci on chromosomes 2 and 15 did not replicate in additional Hispanic/Latino

cohorts. The chromosome 2 locus (2q21.2) is a relative gene desert but overlaps *MGAT5*, which

has been reported to be involved in cancer metastasis and tumor suppression in mice[59] . Further,

transcriptional regulation of the gene is driven by the Ras-Raf-Ets pathway, which is oncogenic[60–

62]. On chromosome 15, the gene closest to the putative risk SNP is *RAB11A*, a member of the

RAS oncogene family, and has been previously associated with risk of lung squamous cell

carcinoma[63] and ovarian cancer[64] . Further, this region contains multiple SNP associations with

blood cell phenotypes[65,66], suggesting a possible connection to the etiology of childhood ALL[15] .

Adjusting for the lead SNP did not strongly attenuate the chromosome 15 association identified

by admixture mapping, suggesting that more complex genomic variation such as structural

variants, which may be in low LD with imputed SNPs[67], could underlie this association and would

require further validation. While there may be biological plausibility for these potentially novel loci,

the lack of replication could also be due to lack of statistical power, heterogeneity of

Hispanic/Latino populations across the United States, or that our initial findings were statistical

artefacts.

Within the genetic epidemiology literature, careful consideration has been given to the use of self-

reported race/ethnicity or genetically inferred ancestry as strata in performing GWAS. For

instance, it is common to define "White British" based on demographic data complemented by

principal components of the genotype data when analyzing UK Biobank to remove concerns of

stratification[68–70]. However, analysis in a relatively homogenous cohort such as the UKB is not

completely free from the effect of stratification[71], and the notion of defining a homogenous subset

of the cohort becomes even more difficult when performing analysis in multi-ancestry cohorts or

admixed populations. In those cases, one can pool samples across all ancestries for a "mega-

analysis"[72] , or perform stratified analysis based on either (1) self-reported demographic

labels[13,32,73] or (2) some arbitrary heuristics using genetically inferred ancestry[14,18,74,75]. The

downside of using genetically inferred ancestry is the prescription of arbitrary thresholds to define

ancestry strata. Across studies, the inclusion criteria vary, with individuals of self-reported White,

Black and Asian race/ethnicity being defined as study participants with over 75-95% European-

like, 50-90% African-like, and 75-90% Asian-like ancestries, respectively[14,18,74–77].

Previous genetic studies involving Hispanic/Latino participants have defined their strata as

individuals whose IA ancestry was greater or equal to 10% *and* greater than the proportion of

African ancestry[75,78,79]. Given the heterogeneity of Hispanics/Latinos as a population, this method

of categorization may prove untenable. The admixture proportions of Hispanic/Latino individuals

vary by country of origin with Caribbean and mainland Hispanics/Latinos exhibiting the highest

levels of African-like and IA-like ancestry, respectively[80,81]. Moreover, the estimated admixture

proportions can vary depending on the reference samples available, as well as the geographic

and temporal definitions of an ancestry component one wishes to estimate. Given these nuances,

we have tended to favor relying on self-reported demographic labels as strata when performing

multi-ancestry GWAS[32,82] or when limiting our analyses to Hispanics/Latinos[12]. Further,

the results of our HARE analysis showed that the algorithm rarely has enough evidence to exclude

an individual from analysis when self-reported labels are present, and imputing missing labels

have low recall rate for a heterogenous population like the Latinos. In cases where self-reported

labels are missing at high proportions, it may be preferable to conduct a mega-analysis instead

of stratified analysis. Indeed, even if overt categorizations impact little of the statistical power of

the study design and may provide a bit more robustness to the study, the underlying message

conveyed by explicit categorization of people based on estimated genetic ancestry may bring

more harm than benefits.

Finally, the results of our study have implications on future investigations of the genetic

architecture of ALL and designs of ancestry-based analyses. As reflected in our findings, the

elevated ALL risk in Hispanic/Latino children is to some extent driven by the higher frequencies

of known ALL risk alleles on IA-like haplotypes, which may underlie the shift towards higher mean

polygenic risk scores for ALL in Hispanic/Latino individuals compared to in non-Latino White

individuals [82,83]. Moreover, these consistent directional associations with risk could be indicative

of a signature of past adaptation. There is some evidence that ALL risk loci, such as the *IKZF1*

locus that we found to be genome-wide significant in admixture mapping, may be under positive

selection in Hispanic/Latino populations[12]. Given the overall enrichment of risk alleles on IA

haplotypes, the selection may be more oligo-genic or polygenic, though careful scrutiny is needed

to rule out other potential confounding[68,84]. Irrespective of whether ALL risk loci are under transient

directional selection, the increased prevalence of risk alleles on IA-like haplotypes suggest that

continued discovery in larger cohorts with IA-like ancestries and/or utilizing mapping approaches

that incorporate signals from both ancestry and allelic associations may be fruitful in discovering

more ALL risk loci and in understanding the genetic contributions to risk disparities.

Acknowledgements

We would like to thank the families and patients who participated in each study for ALL, and Soyoung Jeon for helpful conversations contributing to this research. Data used in this study were generated with supports from multiple grants from the National Institutes of Health (R01CA155461, R01CA175737, R01ES009137, P42ES004705, P50ES018172, P42ES0470518, R24ES028524, P20CA262733, U24ES028524, and R01CA262263), the Environmental Protection Agency (RD83615901), the Cancer Prevention and Research Institute of Texas (RP160771, RP210064), and St. Baldrick's Foundation (consortium grant 522277 with support from the Micaela's Army Foundation). Analysis performed in this study was supported by F31CA278359 to J.L., R01CA262263 to A.J.D., and R35GM142783 to C.W.K.C. A.J.D. is a Scholar of the Leukemia & Lymphoma Society. The content and conclusions from this work do not reflect the official views of the sponsors. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and do not reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. The biospecimens and/or data used in this study were obtained from the California Biobank Program (CBP request #26 and #1380) Section 6555(b), 17 CCR). The California Department of Public Health is not responsible for the results or conclusions drawn by the authors of this publication. Computation of this work is supported by USC's Center for Advanced Research Computing (https://www.carc.usc.edu/).

Data Availability Statement

Genetic data from CCRLP and CCLS were obtained from the California Biobank. Because samples and data are property of the State of California, researchers who would like to request to use the data should establish a protocol with the California Department of Public Health Committee for the Protection of Human Subjects and other relevant agencies to understand if approval to share data are acceptable. The State has provided the following guidance on data sharing, as noted in the following statement: "California has determined that researchers requesting the use of California Biobank biospecimens for their studies will need to seek an exemption from NIH or other granting or funder requirements regarding the uploading of study results into an external bank or repository (including into the NIH dbGaP or other bank or repository). This applies to any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens. Such activities have been determined to violate the statutory scheme at California Health and Safety Code Section 124980 (j), 124991 (b), (g), (h) and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. Investigators may agree to share aggregate data on SNP frequency and their associated p values with other investigators and may upload such frequencies into repositories including the NIH dbGaP repository providing: a) the denominator from which the data is derived includes no fewer than 20,000 individuals; b) no cell count is for <5 individuals; and c) no correlations or linkage probabilities between SNPs are provided." Our data, from CCRLP and CCLS, are each comprised of less than 20,000 subjects and therefore cannot be uploaded to a repository such as dbGaP. Data from Children's Oncology Group and REDIAL were obtained by special request (Yang et al., 2011; Harris et al., 2023). Data from MESA (phs000209.v13.p3) and HCHS/SOL (phs000810.v2.p2.c1, phs000810.v2.p2.c2) were obtained from dbGaP.

References

607
608
1. Bhojwani, D., Yang, J. J. & Pui, C.-H. Biology of Childhood Acute Lymphoblastic Leukemia.

Pediatr. Clin. North Am. **62**, 47–60 (2015).

2. Rheingold, S. R. *et al.* Determinants of survival after first relapse of acute lymphoblastic

leukemia: a Children's Oncology Group study. *Leukemia* **38**, 2382–2394 (2024).

3. Devilli, L. *et al.* Long-term and quality of survival in patients treated for acute lymphoblastic

leukemia during the pediatric age. *Hematol. Rep.* **13**, 8847 (2021).

4. Pui, C.-H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. *The Lancet* **371**,

1030–1043 (2008).

5. Sasaki, K. *et al.* Acute lymphoblastic leukemia: A population-based study of outcome in the

United States based on the surveillance, epidemiology, and end results (SEER) database,

1980–2017. *Am. J. Hematol.* **96**, 650–658 (2021).

6. American Cancer Society. Key Statistics for Acute Lymphocytic Leukemia (ALL). *American*

Cancer Society https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/key-

statistics.html (2024).

7. Feng, Q. *et al.* Trends in Acute Lymphoblastic Leukemia Incidence in the United States by

Race/Ethnicity From 2000 to 2016. *Am. J. Epidemiol.* **190**, 519–527 (2021).

8. Quiroz, E. *et al.* Immunophenotype of acute lymphoblastic leukemia in minorities- analysis

from the SEER database. *Hematol. Oncol.* **40**, 105–110 (2022).

9. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164

(2016).

10.   Mills, M. C. & Rahal, C. The GWAS Diversity Monitor tracks diversity by disease in real

time. *Nat. Genet.* **52**, 242–243 (2020).

11.   de Smith, A. J., Jiménez-Morales, S. & Mejía-Aranguré, J. M. The genetic risk of acute

lymphoblastic leukemia and its implications for children of Latin American origin. *Front.*

Oncol. **13**, 1299355 (2024).

12.   de Smith, A. J. *et al.* A noncoding regulatory variant in IKZF1 increases acute

lymphoblastic leukemia risk in Hispanic/Latino children. *Cell Genomics* **4**, (2024).

13.   Jeon, S., Smith, A. J. & Li, S. Genome-wide trans-ethnic meta-analysis identifies novel

susceptibility loci for childhood acute lymphoblastic leukemia. *Leukemia* **36**, 865–868 (2022).

14.   Vijayakrishnan, J. *et al.* Identification of four novel associations for B-cell acute

lymphoblastic leukaemia risk. *Nat. Commun.* **10**, 5348 (2019).

15.   Kachuri, L. *et al.* Genetic determinants of blood-cell traits influence susceptibility to

childhood acute lymphoblastic leukemia. *Am. J. Hum. Genet.* **108**, 1823–1835 (2021).

16.   Qian, M. *et al.* Novel susceptibility variants at the ERG locus for childhood acute

lymphoblastic leukemia in Hispanics. *Blood* **133**, 724–729 (2019).

17.   Xu, H. *et al.* ARID5B genetic polymorphisms contribute to racial disparities in the

incidence and treatment outcome of childhood acute lymphoblastic leukemia. *J. Clin. Oncol.*

Off. J. Am. Soc. Clin. Oncol. **30**, 751–757 (2012).

18.   Perez-Andreu, V. *et al.* Inherited GATA3 variants are associated with Ph-like childhood

acute lymphoblastic leukemia and risk of relapse. *Nat. Genet.* **45**, 1494–1498 (2013).

19.   Swords, R. *et al.* Acute leukemia in adult Hispanic Americans: a large-population study.

Blood Cancer J. **6**, e484 (2016).

20.   Pollyea, D. A. *et al.* Acute Leukemia in Hispanic Americans: Incidence and Incidence

Rate Differences by Nativity. *Blood* **120**, 3160 (2012).

21.   Dong, Y. *et al.* Leukemia incidence trends at the global, regional, and national level

between 1990 and 2017. *Exp. Hematol. Oncol.* **9**, 14 (2020).

22.   Yi, M., Zhou, L., Li, A., Luo, S. & Wu, K. Global burden and trend of acute

lymphoblastic leukemia from 1990 to 2017. *Aging* **12**, 22869–22891 (2020).

23.   Bryc, K., Durand, E. Y., Macpherson, J. M., Reich, D. & Mountain, J. L. The genetic

ancestry of african americans, latinos, and european Americans across the United States. *Am.*

J. Hum. Genet. **96**, 37–53 (2015).

24.   Homburger, J. R. *et al.* Genomic Insights into the Ancestry and Demographic History of

South America. *PLOS Genet.* **11**, e1005602 (2015).

25.   Walsh, K. *et al.* Associations between genome-wide Native American ancestry, known

risk alleles and B-cell ALL risk in Hispanic children. *Leukemia* **27**, 10.1038/leu.2013.130

(2013).

26.   Florez, J. C. *et al.* Strong association of socioeconomic status with genetic ancestry in

Latinos: implications for admixture studies of type 2 diabetes. *Diabetologia* **52**, 1528–1536

(2009).

27.   Shriver, M. D. *et al.* Skin pigmentation, biogeographical ancestry and admixture

mapping. *Hum. Genet.* **112**, 387–399 (2003).

28.   Qin, H. & Zhu, X. Power comparison of admixture mapping and direct association

analysis in genome-wide association studies. *Genet. Epidemiol.* **36**, 235–243 (2012).

29.   McKeigue, P. M. Prospects for Admixture Mapping of Complex Traits. *Am. J. Hum.*

Genet. **76**, 1–7 (2005).

30.   Committee on the Use of Race, Ethnicity, and Ancestry as Population Descriptors in

Genomics Research *et al. Using Population Descriptors in Genetics and Genomics Research:*

A New Framework for an Evolving Field. 26902 (National Academies Press, Washington, D.C., 2023). doi:10.17226/26902.

31.   Zavala, V. A. *et al.* Cancer health disparities in racial/ethnic minorities in the United States. *Br. J. Cancer* **124**, 315–332 (2021).

32.   Wiemels, J. L. *et al.* GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21. *Nat. Commun.* **9**, 286 (2018).

33.   Ma, X., Buffler, P. A., Layefsky, M., Does, M. B. & Reynolds, P. Control Selection Strategies in Case-Control Studies of Childhood Diseases. *Am. J. Epidemiol.* **159**, 915–921 (2004).

34.   Harris, R. D. *et al.* Ethnic-Specific Predictors of Neurotoxicity Among Pediatric Acute Lymphoblastic Leukemia Patients Following High-Dose Methotrexate. *Cancer* **129**, 1287–1294 (2023).

35.   Sheng, X. *et al.* Inverted genomic regions between reference genome builds in humans impact imputation accuracy and decrease the power of association testing. *Hum. Genet. Genomics Adv.* **4**, (2023).

36.   Maples, B. K., Gravel, S., Kenny, E. E. & Bustamante, C. D. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* **93**, 278–288 (2013).

37.   Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).

38.   Li, S. *et al.* Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children. *PLoS Genet.* **18**, e1010388 (2022).

39.   Kowalski, M. H. *et al.* Use of 100,000 NHLBI Trans-Omics for Precision Medicine

(TOPMed) Consortium whole genome sequences improves imputation quality and detection

of rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet.*

15, 1008500 (2019).

40.   Cahoon, J. L. *et al.* Imputation accuracy across global human populations. *Am. J. Hum.*

Genet. **111**, 979–989 (2024).

41.   Metayer, C. *et al.* Tobacco Smoke Exposure and the Risk of Childhood Acute

Lymphoblastic and Myeloid Leukemias by Cytogenetic Subtype. *Cancer Epidemiol.*

Biomarkers Prev. **22**, 1600–1611 (2013).

42.   R Core Team. R: A Language and Environment for Statistical Computing. R Foundation

for Statistical Computing (2023).

43.   Qian, M. *et al.* Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute

Lymphoblastic Leukemia in Children. *J. Natl. Cancer Inst.* **111**, 1350–1357 (2019).

44.   Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-

Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

45.   Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *GigaScience* **4**, 7 (2015).

46.   Brown, L. A. *et al.* Admixture Mapping Identifies an Amerindian Ancestry Locus

Associated with Albuminuria in Hispanics in the United States. *J. Am. Soc. Nephrol. JASN* **28**,

2211–2220 (2017).

47.   Schick, U. M. *et al.* Genome-wide Association Study of Platelet Count Identifies

Ancestry-Specific Loci in Hispanic/Latino Americans. *Am. J. Hum. Genet.* **98**, 229–242

(2016).

48.   Qin, H. & Zhu, X. Power Comparison of Admixture Mapping and Direct Association

Analysis in Genome-Wide Association Studies. *Genet. Epidemiol.* **36**, 235–243 (2012).

49.   Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

50.   Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in

Genome-wide Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).

51.   Johnson, J. L. & Abecasis, G. R. GAS Power Calculator: web-based power calculator for

genetic association studies. 164343 Preprint at https://doi.org/10.1101/164343 (2017).

52.   Wheeler, D. C., Boyle, J., Carli, M., Ward, M. H. & Metayer, C. Neighborhood

Deprivation, Indoor Chemical Concentrations, and Spatial Risk for Childhood Leukemia. *Int.*

J. Environ. Res. Public. Health **20**, 3582 (2023).

53.   Sun, H. *et al.* The impact of global and local Polynesian genetic ancestry on complex

traits in Native Hawaiians. *PLOS Genet.* **17**, e1009273 (2021).

54.   Asgari, S. *et al.* A positively selected FBN1 missense variant reduces height in Peruvians.

Nature **582**, 234–239 (2020).

55.   Aldrich, M. C. *et al.* Socioeconomic Status and Lung Cancer: Unraveling the

Contribution of Genetic Admixture. *Am. J. Public Health* **103**, e73–e80 (2013).

56.   Non, A. L., Gravlee, C. C. & Mulligan, C. J. Education, Genetic Ancestry, and Blood

Pressure in African Americans and Whites. *Am. J. Public Health* **102**, 1559–1565 (2012).

57.   Wang, L., Gomez, S. L. & Yasui, Y. Racial and Ethnic Differences in Socioeconomic

Position and Risk of Childhood Acute Lymphoblastic Leukemia. *Am. J. Epidemiol.* **185**,

1263–1271 (2017).

58.   Spector, L. G. *et al.* RE: 'RACIAL AND ETHNIC DIFFERENCES IN

SOCIOECONOMIC POSITION AND RISK OF CHILDHOOD ACUTE

LYMPHOBLASTIC LEUKEMIA'. *Am. J. Epidemiol.* **188**, 1192–1193 (2019).

59.   Granovsky, M. *et al.* Suppression of tumor growth and metastasis in Mgat5-deficient

mice. *Nat. Med.* **6**, 306–312 (2000).

60.   Hirata, A. *et al.* Increased risk of metastasis in patients with incidental use of renin-

angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on

electronic medical records. *Hypertens. Res.* **45**, 1869–1881 (2022).

61.   Kang, R. *et al.* Transcriptional Regulation of the N-Acetylglucosaminyltransferase V

Gene in Human Bile Duct Carcinoma Cells (HuCC-T1) Is Mediated by Ets-1 *. *J. Biol. Chem.*

271, 26706–26712 (1996).

62.   Buckhaults, P., Chen, L., Fregien, N. & Pierce, M. Transcriptional Regulation ofN-

Acetylglucosaminyltransferase V by the srcOncogene *. *J. Biol. Chem.* **272**, 19575–19581

(1997).

63.   Gombodorj, N. *et al.* RAB11A Expression Is Associated With Cancer Aggressiveness

Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma. *Ann. Surg.*

Oncol. **29**, 7149–7162 (2022).

64.   Wang, Y., Ren, Y., Li, N., Zhao, J. & Zhao, S. Rab11a promotes the malignant

progression of ovarian cancer by inducing autophagy. *Genes Genomics* **44**, 1375–1384

(2022).

65.   Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases.

Cell **182**, 1214-1231.e11 (2020).

66.   Chen, M.-H. *et al.* Trans-ethnic and ancestry-specific blood-cell genetics in 746,667

individuals from 5 global populations. *Cell* **182**, 1198-1213.e14 (2020).

67.   Sudmant, P. H. *et al.* An integrated map of structural variation in 2,504 human genomes.

Nature **526**, 75–81 (2015).

68.   Sohail, M. *et al.* Polygenic adaptation on height is overestimated due to uncorrected

stratification in genome-wide association studies. *eLife* **8**, e39702 (2019).

69.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

Nature **562**, 203–209 (2018).

70.   Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links

to Common Complex Disease. *Cell* **167**, 1415-1429.e19 (2016).

71.   Chen, M. *et al.* Evidence of Polygenic Adaptation in Sardinia at Height-Associated Loci

Ascertained from the Biobank Japan. *Am. J. Hum. Genet.* **107**, 60–71 (2020).

72.   Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for

complex traits. *Nature* **570**, 514–518 (2019).

73.   Kachuri, L. *et al.* Genetically adjusted PSA levels for prostate cancer screening. *Nat.*

Med. **29**, 1412–1423 (2023).

74.   Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the

Million Veteran Program. *Nat. Genet.* **50**, 1514–1523 (2018).

75.   Xu, H. *et al.* Novel susceptibility variants at 10p12.31-12.2 for childhood acute

lymphoblastic leukemia in ethnically diverse populations. *J. Natl. Cancer Inst.* **105**, 733–742

(2013).

76.   Gautam, Y. *et al.* Genome-wide admixture and association analysis identifies African

ancestry specific risk loci of eosinophilic esophagitis in African American. *J. Allergy Clin.*

Immunol. **151**, 1337–1350 (2023).

77.   Shrine, N. *et al.* Multi-ancestry genome-wide association analyses improve resolution of

genes and pathways influencing lung function and chronic obstructive pulmonary disease risk.

Nat. Genet. **55**, 410–422 (2023).

78.   Archer, N. P. *et al.* Family-based exome-wide association study of childhood acute

lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. *PLOS*

ONE **12**, e0180488 (2017).

79.   Karol, S. E. *et al.* Genetics of ancestry-specific risk for relapse in acute lymphoblastic

leukemia. *Leukemia* **31**, 1325–1332 (2017).

80.   Conomos, M. P. *et al.* Genetic diversity and association studies in US Hispanic/Latino

populations: applications in the Hispanic Community Health Study/Study of Latinos. *Am. J.*

Hum. Genet. **98**, 165–184 (2016).

81.   Bryc, K. *et al.* Genome-wide patterns of population structure and admixture among

Hispanic/Latino populations. *Proc. Natl. Acad. Sci.* **107**, 8954–8961 (2010).

82.   Jeon, S. *et al.* Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci

for childhood acute lymphoblastic leukemia. *Leukemia* **36**, 865–868 (2022).

83.   Jeon, S. *et al.* Evaluating Genomic Polygenic Risk Scores for Childhood Acute

Lymphoblastic Leukemia in Latinos. *MedRxiv Prepr. Serv. Health Sci.* 2023.06.08.23291167

(2023) doi:10.1101/2023.06.08.23291167.

84.   Berg, J. J. *et al.* Reduced signal for polygenic adaptation of height in UK Biobank. *eLife*

8, e39725 (2019).

809